Identification and Validation of a Gene Signature for Lower-Grade Gliomas Based on Pyroptosis-Related Genes to Predict Survival and Response to Immune Checkpoint Inhibitors

Table 1

Clinical information of patients included in this study.

Variables	Group	TCGA (495)	CGGA (408)
Survival status	Alive	370	244
	Dead	125	164
Survival time (median time/days)	—	671	1927
Age	≤40	242	214
	>40	253	193
	Unknown	—	1
Gender	Male	274	236
	Female	221	172
Tumor grade	II	238	220
	III	256	188
	Unknown	1	—